November 18, 2016 - By Darrin Black · 0 Comments
Cerulean Pharma Inc. (NASDAQ:CERU) institutional sentiment decreased to 0.56 in 2016 Q2. Its down -0.17, from 0.73 in 2016Q1. The ratio dropped, as 11 investment managers opened new and increased equity positions, while 15 trimmed and sold stakes in Cerulean Pharma Inc.. The investment managers in our partner’s database now possess: 9.06 million shares, down from 11.38 million shares in 2016Q1. Also, the number of investment managers holding Cerulean Pharma Inc. in their top 10 equity positions decreased from 3 to 2 for a decrease of 1. Sold All: 5 Reduced: 10 Increased: 7 New Position: 4.
Cerulean Pharma Inc. is a clinical-stage, oncology-focused company. The company has a market cap of $20.32 million. The Firm applies its Dynamic Tumor Targeting platform to develop differentiated therapies. It currently has negative earnings. The Company’s platform utilizes nanoparticle-drug conjugates , which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.
About 122,987 shares traded hands. Cerulean Pharma Inc (NASDAQ:CERU) has declined 76.65% since April 18, 2016 and is downtrending. It has underperformed by 81.08% the S&P500.
Analysts await Cerulean Pharma Inc (NASDAQ:CERU) to report earnings on November, 21. They expect $-0.42 EPS, down 7.69% or $0.03 from last year’s $-0.39 per share. After $-0.40 actual EPS reported by Cerulean Pharma Inc for the previous quarter, Wall Street now forecasts 5.00% negative EPS growth.
According to Zacks Investment Research, “Cerulean Pharma Inc. is a clinical-stage oncology-focused company. The Company manufactures therapeutics in the areas of oncology, cardiovascular, autoimmune, and inflammatory diseases as well as tumor cells. Cerulean Pharma Inc. is based in Cambridge, Massachusetts.”
Polaris Venture Management Co. V L.L.C. holds 7.48% of its portfolio in Cerulean Pharma Inc for 3.29 million shares. Sphera Funds Management Ltd. owns 450,000 shares or 0.25% of their US portfolio. Moreover, Deer Vii & Co. Ltd. has 0.16% invested in the company for 166,675 shares. The Maryland-based Rock Springs Capital Management Lp has invested 0.1% in the stock. Granahan Investment Management Inc Ma, a Massachusetts-based fund reported 708,215 shares.#img1#
Ratings analysis reveals 43% of Cerulean Pharmaceuticals’s analysts are positive. Out of 7 Wall Street analysts rating Cerulean Pharmaceuticals, 3 give it “Buy”, 0 “Sell” rating, while 4 recommend “Hold”. The lowest target is $1 while the high is $16. The stock’s average target of $6 is 692.60% above today’s ($0.757) share price. CERU was included in 12 notes of analysts from August 7, 2015. The stock of Cerulean Pharma Inc (NASDAQ:CERU) earned “Overweight” rating by Barclays Capital on Wednesday, February 24. The stock has “Neutral” rating given by Janney Capital on Thursday, August 18. As per Tuesday, September 22, the company rating was initiated by Barclays Capital. Barclays Capital maintained the stock with “Overweight” rating in Tuesday, August 30 report. As per Thursday, August 18, the company rating was downgraded by Leerink Swann. The firm has “Buy” rating by Janney Capital given on Wednesday, January 6. The firm has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The rating was initiated by Roth Capital on Friday, August 28 with “Buy”. The firm has “Market Perform” rating given on Thursday, August 18 by JMP Securities. As per Friday, August 28, the company rating was initiated by TH Capital.
Cerulean Pharma Inc., incorporated on November 28, 2005, is a clinical-stage, oncology-focused company. The Firm applies its Dynamic Tumor Targeting platform to develop differentiated therapies. The Company’s platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads. The Company’s NDC platform is designed to create NDCs that accumulate high concentrations of active drug in tumor cells, without exposure to healthy tissue. The Company’s platform is applicable to a range of payloads. It has created NDCs with a range of small molecule payloads, including Jevtana (cabazitaxel), gemcitabine, methotrexate and Xeljanz (tofacitinib). The Company’s product pipeline consists of CRLX101 and CRLX301. The Company’s CRLX101 is a tumor targeted NDC. The Company’s CRLX301 is an NDC with docetaxel as its anti-cancer payload.
More news for Cerulean Pharma Inc (NASDAQ:CERU) were recently published by: Streetinsider.com, which released: “Form 8-K Cerulean Pharma Inc. For: Nov 17” on November 18, 2016. Quotes.Wsj.com‘s article titled: “News Cerulean Pharma Inc.CERU” and published on April 06, 2014 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Darrin Black